UAE residents now have a fresh option to tackle high cholesterol, as the Emirates Drug Establishment gave the green light to Lipfendra on 1 August 2026. The decision was announced by the federal authority that evaluates and authorises medicines for the Emirates, reinforcing its role in safeguarding public health.
What Lipfendra does
Lipfendra is taken once a day and contains the active ingredient enlicitide. It is intended for adults with elevated low‑density lipoprotein cholesterol, commonly known as LDL‑C, and can be part of a broader plan that includes a balanced diet and regular physical activity. The pill is designed for adults who have already tried lifestyle changes but still need additional support.
LDL cholesterol is often called “bad” cholesterol because high levels raise the risk of cardiovascular disease. The new pill is designed to help lower LDL levels in patients who need additional medical support alongside lifestyle changes. By lowering LDL, the medication helps to mitigate the long‑term risk of heart disease, which remains a leading health concern in the region.
Regulatory approval and its impact
The Emirates Drug Establishment announced that the UAE becomes the second country in the world after the United States to approve this oral treatment. The United States remains the only other nation to have granted this approval, underscoring the UAE’s position at the forefront of medical innovation. The authority said the decision supports efforts to improve the quality of pharmaceutical care in the country.
EDE also highlighted that the approval reflects the efficiency of the UAE’s regulatory system and aims to give patients faster access to innovative medicines, giving doctors another option for patients whose cholesterol needs further intervention. The EDE’s statement noted that the streamlined process aims to reduce waiting times for patients, ensuring that new treatments reach clinics promptly.
Guidance for a heart‑healthy weekend
Health officials urged people with high cholesterol to continue following a balanced diet, stay physically active, and seek medical advice before starting any new medication. The advice aligns with the UAE’s public health campaigns that promote active living and balanced nutrition. A healthcare professional will assess cholesterol levels, medical history and other risk factors before deciding if Lipfendra is suitable.
The authority stressed that the pill should not replace healthy habits. Residents are encouraged to combine any prescribed treatment with lifestyle changes to reduce the risk of cardiovascular disease and improve overall health. Patients are also urged to discuss any concerns about side effects or interactions with their doctors, who can tailor the treatment plan to individual needs.
Frequently asked questions
What is Lipfendra and what does it contain?
Lipfendra is a once-daily oral pill approved in the UAE that contains the active ingredient enlicitide, used to lower LDL (bad) cholesterol in adults.
When did the Emirates Drug Establishment approve Lipfendra?
The Emirates Drug Establishment gave its approval for Lipfendra on 1 August 2026, making the UAE the second country after the United States to authorize the drug.
Who is eligible to take Lipfendra?
Lipfendra is intended for adults who have elevated LDL-C levels and have already tried lifestyle changes such as diet and exercise but still need additional medical support.
How does Lipfendra help reduce the risk of heart disease?
By lowering LDL cholesterol, Lipfendra helps mitigate the long-term risk of cardiovascular disease, complementing a balanced diet and regular physical activity.
Which authority approved Lipfendra in the UAE?
The federal regulator, the Emirates Drug Establishment (EDE), announced the approval of Lipfendra, highlighting the UAE's efficient regulatory system for faster patient access.
